PER® New York Lung Cancer Symposium | Conference

Camidge Breaks Down Oncogene-Driven NSCLC

November 11th 2018

D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non–small cell lung cancer.

Dr. Borghaei on Second-Line Therapy in SCLC

November 10th 2018

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.

Dr. Kris on Adjuvant Systemic Therapy in NSCLC

November 10th 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses adjuvant systemic therapy in patients with non–small cell lung cancer.

Dr. Camidge on Optimal Therapy in EGFR+ NSCLC

November 10th 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

Acquired Resistance Remains Key Challenge in Oncogene-Driven NSCLC

November 9th 2018

Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.

Uncertainty Surrounds Nondriver NSCLC Treatment After Progression

November 9th 2018

Hossein Borghaei, DO, MS, discusses current and potential therapeutic approaches for patients with non-oncogene driven lung cancer who progress on frontline treatment.

Drilon Sheds Light on Lesser-Known Markers in NSCLC

November 9th 2018

Alexander E. Drilon, MD, discusses developing markers in the non–small cell lung cancer paradigm.

Dr. Kris on Sequencing Challenges in Lung Cancer

November 17th 2016

Mark G. Kris, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses challenges associated with sequencing in the treatment of patients with lung cancer.

Optimizing Frontline Immunotherapy in NSCLC

November 15th 2016

Immunotherapy continues to revolutionize the field of non–small cell lung cancer, with researchers now focusing on the optimal use of immune agents in the frontline setting.

Expert Discusses Next Steps With Immunotherapy in Lung Cancer

November 15th 2016

Hossein Borghaei, DO, discuss what lies ahead for immunotherapy in lung cancer, and what changes may be on the horizon for such agents as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) in the frontline setting.

Using PD-L1 Expression to Determine Lung Cancer Treatments

November 15th 2016

Standard of care for newly diagnosed non-small cell lung cancer is shifting to include PD-L1 expression to determine the appropriate treatment plan, says Matthew D. Hellmann, MD.

Dr. Halmos on MET Mutations in Patients With NSCLC

November 15th 2016

Balazs Halmos, MD, director, Thoracic Oncology, director, Clinical Cancer Genomics, Montefiore Medical Center, discusses the prevalence of MET mutations in patients with non–small cell lung cancer (NSCLC).

Dr. West on Considering Factors for EGFR TKIs in NSCLC

November 15th 2016

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses factors he takes into consideration for EGFR tyrosine kinase inhibitors in patients who have EGFR-positive non–small cell lung cancer (NSCLC).

Emerging Data Could Rearrange Frontline EGFR TKIs in NSCLC

November 13th 2016

Individualizing frontline therapy for patients with non–small cell lung cancer based on preferences and clinical experience, as well as efficacy and safety data from pivotal trials, is an appropriate method for selecting EGFR-targeted agents.

Therapeutic Options Expanding for ALK-Rearranged NSCLC

November 13th 2016

The treatment landscape for patients with ALK-rearranged non–small cell lung cancer is changing rapidly, gearing up the potential for more therapeutic options to address the heterogeneity of the mechanism of resistance in this population.

Dr. Perez-Soler on Impact of Osimertinib on Field of NSCLC

November 13th 2016

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non–small cell lung cancer (NSCLC).

Dr. Anne Chiang on Molecular Testing in Lung Cancer Treatment Planning

November 13th 2016

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses molecular testing in lung cancer and how it affects treatment decisions.

Explosion of Novel Agents, Liquid Biopsies Leading Advancements in Lung Cancer Field

November 12th 2016

Lung cancer treatment has undergone a game-changing transformation within the past few years, with a burst of FDA approvals of targeted agents and immunotherapies across a number of indications.

Dr. Oxnard on Delaying Second-Line Treatment in EGFR-Mutant Lung Cancer

November 9th 2015

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

PD-1 Agents Top Choice for Second-Line NSCLC

November 9th 2015

Roman Perez-Soler, MD, expanded on the importance of PD-1 inhibitors for all patients and the role of biomarker testing.